IDDI organized a webinar on the Current Status of Surrogates for Survival in Cancer Trials.
IN THIS WEBINAR, OUR SPEAKERS:
- Provided an overview of the current status of surrogates for overall survival in oncology
- Reviewed the pros and cons of the various efficacy endpoints currently used
- Discussed the currently preferred method for validation of surrogate endpoints
- Presented an overview of the various settings in which disease-free survival and progression-free survival have or have not been considered a valid surrogate for survival
- Illustrated their presentation with several examples, including the evolution of surrogacy within a given setting and potential differences between treatment classes, including immune checkpoint inhibitors.
Drug development in oncology is accelerating at an ever faster pace due to an increasing availability of agents and combinations that need to be assessed in clinical trials. As a result of this fast pace, the choice of endpoints for clinical trials is becoming more critical than ever before. Overall survival, the historical endpoint of choice in phase III, is progressively less suitable as primary endpoint, especially due to the time and resources that are necessary to reliably assess it, and also because of the increasing availability of salvage therapies that confound the effect of treatment on survival. These drawbacks of overall survival set the stage for surrogates like disease-free survival and progression-free survival, which are used with the goal of expediting clinical research. However, there has been a recurrent concern that some of these endpoints have not been properly validated as surrogates for survival.
SPEAKERS:
